Recent Updates
Recently added Catalysts
BRVE Positive Sentiment

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

Monday, March 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Hengrui Pharma and Braveheart Bio have announced positive results from a Phase 2 study of HRS/BHB-1893 for obstructive hypertrophic cardiomyopathy. The treatment demonstrated significant efficacy with rapid reductions in left ventricular outflow tract. The study suggests a best-in-class profile, emphasizing safety and ease of use with a simplified dosing regimen.

Market Sentiment Analysis

POSITIVE FACTORS

  • HRS-1893 shows potential for best-in-class clinical profile.
  • Rapid and substantial reductions in left ventricular outflow tract.
  • Simplified dosing regimen with minimal to no titration necessary.

Full Press Release Details

Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of use, including simplified dosing regimen with minimal to no titration necessary HRS-1893 treatment resulted in rapid and substantial reductions in left ventricular outflow tract

Frequently Asked Questions

What is HRS/BHB-1893 used for?

HRS/BHB-1893 is being studied for its efficacy in treating obstructive hypertrophic cardiomyopathy.

What were the results of the Phase 2 study?

The Phase 2 study showed rapid and substantial reductions in left ventricular outflow tract.

What advantages does HRS/BHB-1893 offer?

It offers a best-in-class clinical profile with a simplified dosing regimen and minimal titration.

Who conducted the Phase 2 study?

The study was conducted by Hengrui Pharma and Braveheart Bio.

ShareAdd on Google
Tags: BRVE Hengrui Pharma Braveheart Bio HRS-1893 obstructive hypertrophic cardiomyopathy clinical trial
Last updated: Mar 30, 2026

Biotech snapshot

Cash runway
$123M liquidity · $5M/mo burn
~22 mo
Low dilution risk